Decoding the RNA Frontier: RealSeq Biosciences' Breakthrough in Fragmentomics Diagnostics
RealSeq awarded NHGRI grant to develop novel RNA “fragmentomics” technology
In the ever-evolving realm of genomic research, RealSeq Biosciences has made a notable leap forward. They're diving deep into the intricate world of RNA fragmentomics, aiming to use it as a real-time diagnostic tool for diseases. And the National Human Genome Research Institute (NHGRI) has taken note, awarding them a grant to develop an advanced small RNA-seq NGS technology.
What's this all about? In essence, the grant titled, "Preparation of sequencing libraries for multi-analyte analysis of small RNAs," will boost the creation of RealSeq®-RF technology. This innovation is set to revolutionize our understanding of RNA fragmentomics by offering detailed analysis. It's designed to detect every small RNA type and fragment found in biofluids with impressive specificity.
In the grander scheme, this fits snugly into RealSeq Biosciences' broader initiative: the RiboMarker®. This initiative focuses on RNA fragmentomics-based diagnostics, targeting diseases like Valley Fever, which is becoming increasingly prevalent due to climate change's influence.
Sergio Barberan-Soler, Ph.D., the enthusiastic CEO of RealSeq Biosciences, expressed the company's excitement over the grant, emphasizing its importance in advancing small RNA biomarker discovery. The RealSeq-RF, he noted, is a groundbreaking addition to their existing small RNA-seq platform. It addresses existing technical challenges and allows for a detailed view of the RNA fragmentome in biofluids. This includes small non-coding RNAs and larger coding fragments, vital for understanding biomarkers and facilitating liquid biopsies.
Sergei Kazakov, Ph.D., the CSO of RealSeq Biosciences and the Principal Investigator of this grant, sees the development of RealSeq-RF as a strategic move to lead in the RNA fragmentome domain. For researchers, it's an exciting tool that could unravel the mysteries of small RNAs in health and disease scenarios.
Looking at the bigger picture, RealSeq Biosciences is on an upward trajectory. By 2023, they anticipate record-breaking revenues, gaining significant trust from both academic institutions and the pharma-biotech sectors.
About RealSeq Biosciences
Nestled in Santa Cruz, California, this private biotech enterprise is at the forefront of RNA fragmentomics. Their pioneering approach to diagnostics based on RNA fragmentomics is shaping a new future, where dynamic markers of diseases become the norm.